{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:34:46Z","timestamp":1778855686078,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T00:00:00Z","timestamp":1457481600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T00:00:00Z","timestamp":1457481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FA 466\/4-1"],"award-info":[{"award-number":["FA 466\/4-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KR4371\/1-1"],"award-info":[{"award-number":["KR4371\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Seventh Framework Programme","award":["259735"],"award-info":[{"award-number":["259735"]}]},{"name":"Interdisciplinary Research Center, Univesity of W\u00fcrzburg","award":["Z-2\/57"],"award-info":[{"award-number":["Z-2\/57"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HORM CANC"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s12672-016-0260-7","type":"journal-article","created":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T14:51:12Z","timestamp":1457535072000},"page":"211-218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide"],"prefix":"10.1007","volume":"7","author":[{"name":"on behalf of the German Adrenocortical Carcinoma Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7628-3161","authenticated-orcid":false,"given":"Matthias","family":"Kroiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Deutschbein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiebke","family":"Schl\u00f6telburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina L.","family":"Ronchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Neu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Helge","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Quinkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Hahner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"Heidemeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,9]]},"reference":[{"key":"260_CR1","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1002\/cncr.23886","volume":"113","author":"KY Bilimoria","year":"2008","unstructured":"Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, Sturgeon C (2008) Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113:3130\u20133136","journal-title":"Cancer"},{"key":"260_CR2","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1210\/jc.2008-2291","volume":"94","author":"SH Golden","year":"2009","unstructured":"Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW (2009) Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 94:1853\u20131878","journal-title":"J Clin Endocrinol Metab"},{"key":"260_CR3","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1210\/jc.2013-3020","volume":"98","author":"M Fassnacht","year":"2013","unstructured":"Fassnacht M, Kroiss M, Allolio B (2013) Update in adrenocortical carcinoma. J Clin Endocrinol Metab 98:4551\u20134564","journal-title":"J Clin Endocrinol Metab"},{"key":"260_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1210\/er.2013-1029","volume":"35","author":"T Else","year":"2014","unstructured":"Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, Jolly S, Miller BS, Giordano TJ, Hammer GD (2014) Adrenocortical carcinoma. Endocr Rev 35:282\u2013326","journal-title":"Endocr Rev"},{"key":"260_CR5","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJM199004263221705","volume":"322","author":"JP Luton","year":"1990","unstructured":"Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P, Bonnin A, Bricaire H (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322:1195\u20131201","journal-title":"N Engl J Med"},{"key":"260_CR6","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/bjc.1994.183","volume":"69","author":"HR Haak","year":"1994","unstructured":"Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ, Krans HM (1994) Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69:947\u2013951","journal-title":"Br J Cancer"},{"key":"260_CR7","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2","volume":"92","author":"E Baudin","year":"2001","unstructured":"Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G, Schlumberger M (2001) Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o, p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92:1385\u20131392","journal-title":"Cancer"},{"key":"260_CR8","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1210\/jc.2013-2281","volume":"98","author":"TM Kerkhofs","year":"2013","unstructured":"Kerkhofs TM, Baudin E, Terzolo M, Allolio B, Chadarevian R, Mueller HH, Skogseid B, Leboulleux S, Mantero F, Haak HR, Fassnacht M (2013) Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab 98:4759\u20134767","journal-title":"J Clin Endocrinol Metab"},{"key":"260_CR9","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1677\/ERC-08-0103","volume":"15","author":"F Daffara","year":"2008","unstructured":"Daffara F, De Francia S, Reimondo G, Zaggia B, Aroasio E, Porpiglia F, Volante M, Termine A, Di Carlo F, Dogliotti L, Angeli A, Berruti A, Terzolo M (2008) Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 15:1043\u20131053","journal-title":"Endocr Relat Cancer"},{"key":"260_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1530\/EJE-10-0956","volume":"164","author":"NP van Erp","year":"2011","unstructured":"van Erp NP, Guchelaar HJ, Ploeger BA, Romijn JA, Hartigh J, Gelderblom H (2011) Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol 164:621\u2013626","journal-title":"Eur J Endocrinol"},{"key":"260_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1365-2265.2011.04214.x","volume":"75","author":"M Kroiss","year":"2011","unstructured":"Kroiss M, Quinkler M, Lutz WK, Allolio B, Fassnacht M (2011) Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 75:585\u2013591","journal-title":"Clin Endocrinol (Oxf)"},{"key":"260_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1210\/jc.2012-2851","volume":"98","author":"V Chortis","year":"2013","unstructured":"Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O'Neil DM, Libe R, Allolio B, Bertagna X, Bertherat J, Beuschlein F, Fassnacht M, Karavitaki N, Mannelli M, Mantero F, Opocher G, Porfiri E, Quinkler M, Sherlock M, Terzolo M, Nightingale P, Shackleton CH, Stewart PM, Hahner S, Arlt W (2013) Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5alpha-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab 98:161\u2013171","journal-title":"J Clin Endocrinol Metab"},{"key":"260_CR13","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1210\/jc.2010-2676","volume":"96","author":"IG Hermsen","year":"2011","unstructured":"Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, Daffara F, Berruti A, Chadarevian R, Schlumberger M, Allolio B, Haak HR, Baudin E (2011) Plasma concentrations of o, p'DDD, o, p'DDA, and o, p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 96:1844\u20131851","journal-title":"J Clin Endocrinol Metab"},{"key":"260_CR14","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s12020-014-0517-2","volume":"49","author":"D Theile","year":"2015","unstructured":"Theile D, Haefeli WE, Weiss J (2015) Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro. Endocrine 49:842\u2013853","journal-title":"Endocrine"},{"key":"260_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/MED.0000000000000056","volume":"21","author":"M Terzolo","year":"2014","unstructured":"Terzolo M, Zaggia B, Allasino B, De Francia S (2014) Practical treatment using mitotane for adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes 21:159\u2013165","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"260_CR16","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1210\/en.2015-1367","volume":"156","author":"S Sbiera","year":"2015","unstructured":"Sbiera S, Leich E, Liebisch G, Sbiera I, Schirbel A, Wiemer L, Matysik S, Eckhardt C, Gardill F, Gehl A, Kendl S, Weigand I, Bala M, Ronchi CL, Deutschbein T, Schmitz G, Rosenwald A, Allolio B, Fassnacht M, Kroiss M (2015) Mitotane inhibits sterol-o-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology 156:3895\u20133908","journal-title":"Endocrinology"},{"key":"260_CR17","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardiere C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Muller HH, Skogseid B, Group F-AS (2012) Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366:2189\u20132197","journal-title":"N Engl J Med"},{"key":"260_CR18","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1677\/erc.1.01025","volume":"12","author":"A Berruti","year":"2005","unstructured":"Berruti A, Terzolo M, Sperone P, Pia A, Casa SD, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L (2005) Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12:657\u2013666","journal-title":"Endocr Relat Cancer"},{"key":"260_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1677\/ERC-09-0281","volume":"17","author":"P Sperone","year":"2010","unstructured":"Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, Vincenzi B, Badalamenti G, Intrivici C, Del Buono S, De Francia S, Kalomirakis E, Ratti R, Angeli A, Dogliotti L, Papotti M, Terzolo M, Berruti A (2010) Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer 17:445\u2013453","journal-title":"Endocr Relat Cancer"},{"key":"260_CR20","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1210\/jc.2007-2564","volume":"93","author":"M Quinkler","year":"2008","unstructured":"Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritter C, Strasburger C, Allolio B, Fassnacht M (2008) Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 93:2057\u20132062","journal-title":"J Clin Endocrinol Metab"},{"key":"260_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1530\/EJE-09-0804","volume":"162","author":"S Wortmann","year":"2010","unstructured":"Wortmann S, Quinkler M, Ritter C, Kroiss M, Johanssen S, Hahner S, Allolio B, Fassnacht M (2010) Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol 162:349\u2013356","journal-title":"Eur J Endocrinol"},{"key":"260_CR22","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1210\/jc.2012-1419","volume":"97","author":"M Kroiss","year":"2012","unstructured":"Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, Pollinger A, Laubner K, Strasburger CJ, Hahner S, Muller HH, Allolio B, Fassnacht M (2012) Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab 97:3495\u20133503","journal-title":"J Clin Endocrinol Metab"},{"key":"260_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/EJE-11-0918","volume":"166","author":"A Berruti","year":"2012","unstructured":"Berruti A, Sperone P, Ferrero A, Germano A, Ardito A, Priola AM, De Francia S, Volante M, Daffara F, Generali D, Leboulleux S, Perotti P, Baudin E, Papotti M, Terzolo M (2012) Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol 166:451\u2013458","journal-title":"Eur J Endocrinol"},{"key":"260_CR24","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","volume":"16","author":"M Fassnacht","year":"2015","unstructured":"Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD (2015) Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol 16:426\u2013435","journal-title":"Lancet Oncol"},{"key":"260_CR25","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12672-011-0087-1","volume":"2","author":"A Berruti","year":"2011","unstructured":"Berruti A, Sperone P, Bellini E, Daffara F, Perotti P, Ardito A, Saini A, Terzolo M (2011) Metronomic therapy concepts in the management of adrenocortical carcinoma. Horm Cancer 2:378\u2013384","journal-title":"Horm Cancer"},{"key":"260_CR26","first-page":"148","volume":"36","author":"A Ferrero","year":"2013","unstructured":"Ferrero A, Sperone P, Ardito A, Rossi G, Del Buono S, Priola AM, Bracarda S, Taberna E, Terzolo M, Berruti A (2013) Metronomic chemotherapy may be active in heavily pre-treated patients with metastatic adreno-cortical carcinoma. J Endocrinol Investig 36:148\u2013152","journal-title":"J Endocrinol Investig"},{"key":"260_CR27","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1159\/000081342","volume":"27","author":"D Latz","year":"2004","unstructured":"Latz D, Nassar N, Frank R (2004) Trofosfamide in the palliative treatment of cancer: a review of the literature. Oncol Res Treat 27:572\u2013576","journal-title":"Oncol Res Treat"},{"key":"260_CR28","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1517\/17425255.2010.487861","volume":"6","author":"B Giraud","year":"2010","unstructured":"Giraud B, Hebert G, Deroussent A, Veal GJ, Vassal G, Paci A (2010) Oxazaphosphorines: new therapeutic strategies for an old class of drugs. Expert Opin Drug Metab Toxicol 6:919\u2013938","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"260_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000227672","volume":"54","author":"E Salminen","year":"1997","unstructured":"Salminen E, Nikkanen V, Lindholm L (1997) Palliative chemotherapy in non-Hodgkin's lymphoma. Oncology 54:108\u2013111","journal-title":"Oncology"},{"key":"260_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/BF00685858","volume":"36","author":"C Blomqvist","year":"1995","unstructured":"Blomqvist C, Wiklund T, Pajunen M, Virolainen M, Elomaa I (1995) Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma. Cancer Chemother Pharmacol 36:263\u2013265","journal-title":"Cancer Chemother Pharmacol"},{"key":"260_CR31","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1081\/CNV-100107742","volume":"19","author":"E Gunsilius","year":"2001","unstructured":"Gunsilius E, Gierlich T, Mross K, Gastl G, Unger C (2001) Palliative chemotherapy in pretreated patients with advanced cancer: oral trofosfamide is effective in ovarian carcinoma. Cancer Investig 19:808\u2013811","journal-title":"Cancer Investig"},{"key":"260_CR32","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/cncr.24030","volume":"115","author":"M Fassnacht","year":"2009","unstructured":"Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B (2009) Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 115:243\u2013250","journal-title":"Cancer"},{"key":"260_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00000478-198403000-00001","volume":"8","author":"LM Weiss","year":"1984","unstructured":"Weiss LM (1984) Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 8:163\u2013169","journal-title":"Am J Surg Pathol"},{"key":"260_CR34","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","volume":"26","author":"R Libe","year":"2015","unstructured":"Libe R, Borget I, Ronchi CL, Zaggia B, Kroiss M, Kerkhofs T, Bertherat J, Volante M, Quinkler M, Chabre O, Bala M, Tabarin A, Beuschlein F, Vezzosi D, Deutschbein T, Borson-Chazot F, Hermsen I, Stell A, Fottner C, Leboulleux S, Hahner S, Mannelli M, Berruti A, Haak H, Terzolo M, Fassnacht M, Baudin E, network E (2015) Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): a European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol 26:2119\u20132125","journal-title":"Ann Oncol"},{"key":"260_CR35","doi-asserted-by":"publisher","unstructured":"Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, F\u00fchrer D, Jurowich C, Quinkler M, Petersenn S, Spahn M, Hahner S, Allolio B (2010) Improved survival in patients with stage II adrenocortical carcinoma followed prospectively by specialized centers. J Clin Endocrinol Metab 95(11):4925\u201332. doi:10.1210\/jc.2010-0803","DOI":"10.1210\/jc.2010-0803"},{"key":"260_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"260_CR37","first-page":"386","volume":"6","author":"S Hahner","year":"2005","unstructured":"Hahner S, Fassnacht M (2005) Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 6:386","journal-title":"Curr Opin Investig Drugs"},{"key":"260_CR38","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1158\/1535-7163.MCT-11-0634","volume":"11","author":"F Meng","year":"2012","unstructured":"Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, Duan JX, Cai X, Mowday AM, Guise CP, Maroz A, Anderson RF, Patterson AV, Stachelek GC, Glazer PM, Matteucci MD, Hart CP (2012) Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther 11:740\u2013751","journal-title":"Mol Cancer Ther"},{"key":"260_CR39","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1158\/0008-5472.CAN-15-1107","volume":"75","author":"FW Hunter","year":"2015","unstructured":"Hunter FW, Young RJ, Shalev Z, Vellanki RN, Wang J, Gu Y, Joshi N, Sreebhavan S, Weinreb I, Goldstein DP, Moffat J, Ketela T, Brown KR, Koritzinsky M, Solomon B, Rischin D, Wilson WR, Wouters BG (2015) Identification of P450 oxidoreductase as a major determinant of sensitivity to hypoxia-activated prodrugs. Cancer Res 75:4211\u20134223","journal-title":"Cancer Res"},{"key":"260_CR40","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1200\/JCO.2014.55.7504","volume":"33","author":"MJ Borad","year":"2015","unstructured":"Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, Schelman WR, Stephenson J Jr, Chiorean EG, Rosen PJ, Ulrich B, Dragovich T, Del Prete SA, Rarick M, Eng C, Kroll S, Ryan DP (2015) Randomized phase II Trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 33:1475\u20131481","journal-title":"J Clin Oncol"},{"key":"260_CR41","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1200\/JCO.2013.54.3660","volume":"32","author":"SP Chawla","year":"2014","unstructured":"Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, Adkins DR, Hendifar AE, Kroll S, Ganjoo KN (2014) Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol 32:3299\u20133306","journal-title":"J Clin Oncol"}],"container-title":["Hormones and Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-016-0260-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12672-016-0260-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-016-0260-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-016-0260-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T17:51:15Z","timestamp":1609264275000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12672-016-0260-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,9]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["260"],"URL":"https:\/\/doi.org\/10.1007\/s12672-016-0260-7","relation":{},"ISSN":["1868-8497","1868-8500"],"issn-type":[{"value":"1868-8497","type":"print"},{"value":"1868-8500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,9]]},"assertion":[{"value":"28 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"These studies were approved by the ethics committee of the University of W\u00fcrzburg (approval number 86\/03 and 88\/11), and written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Grants"}},{"value":"The authors declare that they have no conflict of interest","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}